Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey I Shapiro

Showing results (51-60 of 277) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5pRenyan Liu, Xin Wang, Timothy B Branigan, et al.
British Journal of Cancer|January 20, 2017
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanomaAdil Daud, Harriet M Kluger, Razelle Kurzrock, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.
Cancer Immunology, Immunotherapy : CII|March 21, 2021
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumorsKhanh T Do, Claire Manuszak, Emily Thrash, et al.
Investigational New Drugs|January 11, 2017
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumorsGeoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, et al.
Cancers|June 10, 2022
Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast CancerNami Yamashita, Atsushi Fushimi, Yoshihiro Morimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancerGautam Maulik, Takashi Kijima, Patrick C Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Synergy of WEE1 and mTOR Inhibition in Mutant <i>KRAS</i>-Driven Lung CancersJosephine Hai, Shengwu Liu, Lauren Bufe, et al.
Investigational New Drugs|April 18, 2019
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumorsJeffrey P Sharman, Jennifer J Wheler, Lawrence Einhorn, et al.
Pageof 28

Showing results (51-60 of 277) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5pRenyan Liu, Xin Wang, Timothy B Branigan, et al.
British Journal of Cancer|January 20, 2017
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanomaAdil Daud, Harriet M Kluger, Razelle Kurzrock, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.
Cancer Immunology, Immunotherapy : CII|March 21, 2021
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumorsKhanh T Do, Claire Manuszak, Emily Thrash, et al.
Investigational New Drugs|January 11, 2017
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumorsGeoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, et al.
Cancers|June 10, 2022
Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast CancerNami Yamashita, Atsushi Fushimi, Yoshihiro Morimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancerGautam Maulik, Takashi Kijima, Patrick C Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Synergy of WEE1 and mTOR Inhibition in Mutant <i>KRAS</i>-Driven Lung CancersJosephine Hai, Shengwu Liu, Lauren Bufe, et al.
Investigational New Drugs|April 18, 2019
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumorsJeffrey P Sharman, Jennifer J Wheler, Lawrence Einhorn, et al.
Pageof 28